Fondazione Michelangelo

Recent papers from Fondazione Michelangelo

1. Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapynpj Precision Oncology · 2026
2. Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancerThe Breast · 2026
3. Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cellsCell Reports Methods · 2026
4. Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trialAnnals of Oncology · 2026
5. Abstract 6752: Mapping the spatial organisation of B cells and immune signalling in TNBC to characterise response to immunotherapyCancer Research · 2026
6. Toxicity impacts evolution in the Environmental Footprint methods: an example-based interpretation of the resultsThe International Journal of Life Cycle Assessment · 2026
7. Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast CancerNew England Journal of Medicine · 2026
8. Abstract PS2-09-09: Early on-treatment PD-L1 expression and stromal tumor infiltrating lymphocytes (sTILs) refine the prediction of EFS in the NeoTRIP trialClinical Cancer Research · 2026
9. Abstract RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)Clinical Cancer Research · 2026
10. Computational Methods for Cancer Neoantigen PredictionSpringer · 2025
11. Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancernpj Breast Cancer · 2025
12. Investigating methodological aspects of absolute environmental sustainability assessment based on planetary boundariesEnvironmental Impact Assessment Review · 2025
13. Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.2025
14. Genome-wide transcriptomic response of whole blood to radiationScientific Reports · 2025
15. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT studyESMO Open · 2025
16. Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic dataMolecular Oncology · 2025
17. Prognostic and biological roles of Parkinson’s disease genes in cancer2025
18. Genome-wide transcriptomic response of whole blood to radiation2025
19. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapiesNature Communications · 2025
20. Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerCancer Research · 2024